Cargando…

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?

PURPOSE: The aim of this study was to compare a surgical with a Phoenix-derived definition of cure at 4 years after treatment by (125)J low-dose-rate brachytherapy (LDR-BT) in patients with low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: A total of 427 evaluable men with low-risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Boehle, Andreas, Zywietz, Dorothea, Robrahn-Nitschke, Irina, Koenig, Inke R., Lusch, Achim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943771/
https://www.ncbi.nlm.nih.gov/pubmed/36845613
http://dx.doi.org/10.1016/j.adro.2022.101112
_version_ 1784891778386624512
author Boehle, Andreas
Zywietz, Dorothea
Robrahn-Nitschke, Irina
Koenig, Inke R.
Lusch, Achim
author_facet Boehle, Andreas
Zywietz, Dorothea
Robrahn-Nitschke, Irina
Koenig, Inke R.
Lusch, Achim
author_sort Boehle, Andreas
collection PubMed
description PURPOSE: The aim of this study was to compare a surgical with a Phoenix-derived definition of cure at 4 years after treatment by (125)J low-dose-rate brachytherapy (LDR-BT) in patients with low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: A total of 427 evaluable men with low-risk (62.8%) and intermediate-risk (37.2%) prostate cancer were treated with LDR-BT (160 Gy). Cure was defined at 4 years either as not having experienced a biochemical recurrence by the Phoenix definition, or by a surgical definition, using a posttreatment prostate-specific antigen of ≤0.2 ng/mL. Biochemical recurrence–free survival (BRFS), metastasis-free survival (MFS), and cancer-specific survival were calculated at 5 and 10 years using the Kaplan-Meier method. Standard diagnostic test evaluations were used to compare both definitions with regard to later metastatic failure or cancer-specific death. RESULTS: At 48 months, 427 patients were evaluable with a Phoenix-defined and 327 with a surgical-defined cure. At 5 and 10 years BRFS was 97.4% and 89% and MFS was 99.5% and 96.3% in the Phoenix-defined cure cohort, and BRFS was 98.2% and 92.7% and MFS was 100% and 99.4% in the surgical-defined cure cohort. Specificity for cure was 100% for both definitions. Sensitivity was 97.4% for the Phoenix and 96.3% for the surgical definition. The positive predictive value was 100% for both, whereas the negative predictive value was 29% for the Phoenix and 7.7% for the surgical definition. Accuracies of a correct prediction of cure were 94.8% and 96.3% for the Phoenix and the surgical definition, respectively. CONCLUSIONS: Both definitions are useful for a reliable assessment of cure after LDR-BT in patients with low-risk and intermediate-risk prostate cancer. Cured patients might follow a less stringent follow-up schedule from 4 years onward, whereas patients not achieving cure at 4 years should be monitored for an extended time.
format Online
Article
Text
id pubmed-9943771
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99437712023-02-23 Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical? Boehle, Andreas Zywietz, Dorothea Robrahn-Nitschke, Irina Koenig, Inke R. Lusch, Achim Adv Radiat Oncol Scientific Article PURPOSE: The aim of this study was to compare a surgical with a Phoenix-derived definition of cure at 4 years after treatment by (125)J low-dose-rate brachytherapy (LDR-BT) in patients with low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: A total of 427 evaluable men with low-risk (62.8%) and intermediate-risk (37.2%) prostate cancer were treated with LDR-BT (160 Gy). Cure was defined at 4 years either as not having experienced a biochemical recurrence by the Phoenix definition, or by a surgical definition, using a posttreatment prostate-specific antigen of ≤0.2 ng/mL. Biochemical recurrence–free survival (BRFS), metastasis-free survival (MFS), and cancer-specific survival were calculated at 5 and 10 years using the Kaplan-Meier method. Standard diagnostic test evaluations were used to compare both definitions with regard to later metastatic failure or cancer-specific death. RESULTS: At 48 months, 427 patients were evaluable with a Phoenix-defined and 327 with a surgical-defined cure. At 5 and 10 years BRFS was 97.4% and 89% and MFS was 99.5% and 96.3% in the Phoenix-defined cure cohort, and BRFS was 98.2% and 92.7% and MFS was 100% and 99.4% in the surgical-defined cure cohort. Specificity for cure was 100% for both definitions. Sensitivity was 97.4% for the Phoenix and 96.3% for the surgical definition. The positive predictive value was 100% for both, whereas the negative predictive value was 29% for the Phoenix and 7.7% for the surgical definition. Accuracies of a correct prediction of cure were 94.8% and 96.3% for the Phoenix and the surgical definition, respectively. CONCLUSIONS: Both definitions are useful for a reliable assessment of cure after LDR-BT in patients with low-risk and intermediate-risk prostate cancer. Cured patients might follow a less stringent follow-up schedule from 4 years onward, whereas patients not achieving cure at 4 years should be monitored for an extended time. Elsevier 2022-10-21 /pmc/articles/PMC9943771/ /pubmed/36845613 http://dx.doi.org/10.1016/j.adro.2022.101112 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Boehle, Andreas
Zywietz, Dorothea
Robrahn-Nitschke, Irina
Koenig, Inke R.
Lusch, Achim
Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
title Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
title_full Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
title_fullStr Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
title_full_unstemmed Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
title_short Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
title_sort definitions of “cure” after low-dose-rate brachytherapy in low- and intermediate-risk prostate cancer: phoenix or surgical?
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943771/
https://www.ncbi.nlm.nih.gov/pubmed/36845613
http://dx.doi.org/10.1016/j.adro.2022.101112
work_keys_str_mv AT boehleandreas definitionsofcureafterlowdoseratebrachytherapyinlowandintermediateriskprostatecancerphoenixorsurgical
AT zywietzdorothea definitionsofcureafterlowdoseratebrachytherapyinlowandintermediateriskprostatecancerphoenixorsurgical
AT robrahnnitschkeirina definitionsofcureafterlowdoseratebrachytherapyinlowandintermediateriskprostatecancerphoenixorsurgical
AT koeniginker definitionsofcureafterlowdoseratebrachytherapyinlowandintermediateriskprostatecancerphoenixorsurgical
AT luschachim definitionsofcureafterlowdoseratebrachytherapyinlowandintermediateriskprostatecancerphoenixorsurgical